Exero Medical

What Exero Medical does

Exero Medical is a privately held medical device company founded in 2018 and headquartered across Or Yehuda, Israel and Jersey City, New Jersey. The company is developing the xBar system, a post-operative tissue monitoring platform that embeds electrode sensors within a standard surgical drain placed at the anastomosis site during gastrointestinal surgery. The sensors capture electrophysiological data — specifically tissue impedance and intrinsic bowel myoelectric signals — which are wirelessly transmitted to a cloud platform where proprietary machine learning algorithms analyze the data stream to assess tissue healing status and classify it into "Leak States" that indicate risk of post-operative complications. The xBar Clinician App presents the resulting analysis to support post-operative care decisions.

The company targets acute care hospitals and medical centers performing colorectal resection surgery, where anastomotic leaks remain a serious complication often identified only after significant clinical deterioration. Pivotal study results announced in May 2026 reported 100% sensitivity and 88% specificity in detecting leaks by post-operative day 3 across 222 patients enrolled at 12 medical centers in the US and Israel, with leaks identified on average 3.9 days earlier than standard clinical practice. Exero has been granted FDA Breakthrough Device Designation and patents in the US and China, and it submitted a De Novo application to the FDA with planned US commercial launch targeted for 2027.

Exero Medical is pre-revenue, with the xBar system currently limited by US law to investigational use. The company has raised approximately $14M to date across a $1.3M SAFE (2021) and a $12.7M preferred seed round (2025). Its intended revenue model is direct enterprise sales of disposable hardware devices to hospitals performing colorectal surgery, with potential future licensing of the biosensor platform into additional GI indications. Go-to-market relies on enterprise field sales, scientific publication and conference presence (ASCRS, SAGES), and clinical KOL relationships through a scientific advisory board that includes leading colorectal surgeons from major US and Israeli medical centers.

Name

Exero Medical

Legal name

Exero Medical

Website

https://exeromedical.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Exero Medical is a pre-revenue medical device company developing the xBar system, which uses electrode-embedded surgical drains and proprietary AI to detect post-operative anastomotic leaks for hospitals performing gastrointestinal surgery.

Ownership category

akta.pro rank

Product category

Surgical Monitoring Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity) (HLAHADAE)

Keywords

• Post-operative tissue monitoring
• Colorectal anastomotic leak detection
• Biosensor medical devices
• Electrophysiological tissue sensing
• GI surgical complication monitoring

Headquarters

HQ city

Or Yehuda

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. xBar System Commercialization: Pre-revenue company with the xBar system in clinical development. The company plans to commercialize its tissue monitoring system for post-operative care in gastrointestinal surgery following FDA De Novo clearance, targeting U.S. market entry in 2027. Revenue model likely to involve device sales or rental to hospitals.
2. Sensor Technology Licensing: The company may pursue licensing opportunities for its biosensor technology platform beyond GI surgery, with ongoing research to expand the potential use and form factor of xBar into other populations and indications within the gastrointestinal tract.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Exero Medical develops and sells the xBar System, a post-operative tissue monitoring medical device for gastrointestinal surgery patients. The system consists of electrode sensors embedded within a standard surgical drain placed near the anastomosis site during surgery, an external recording device that wirelessly transmits captured electrophysiological data (tissue impedance and bowel myoelectric signals) to a cloud platform, and a clinician app that displays tissue healing status. Proprietary AI/ML algorithms analyze the data to detect early signs of complications such as anastomotic leaks, with clinical results demonstrating 100% sensitivity and 88% specificity by post-operative day 3.

Product overview

Exero Medical offers a single unified product, the xBar system, consisting of three integrated components: electrode sensors embedded in a standard surgical drain, an external recording device that transmits data to the cloud, and a clinician app that presents analysis results. The system provides continuous post-operative monitoring of tissue healing following gastrointestinal surgery using proprietary AI algorithms to detect anastomotic leaks earlier than standard clinical practice.

Differentiator

Problem solved

Functional benefit

Products and services

• xBar System A post-operative tissue monitoring system using electrode sensors embedded within a standard surgical drain to capture electrophysiological data (tissue impedance and bowel myoelectric signals) from the surgical site, with data wirelessly transmitted to a cloud platform and analyzed by proprietary AI/ML algorithms to track tissue recovery and detect early signs of complications such as anastomotic leaks in gastrointestinal surgery patients. For acute care hospitals, surgeons, and post-operative care teams performing or managing patients after colorectal resection surgery.

Quantifiable outcome

• 100% sensitivity and 88% specificity in detecting anastomotic leaks by post-operative day 3 in 222-patient pivotal study
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• MEDX XeleratorcoreStrategic or Co-development Partner · 1 January 2018Founded Exero Medical in 2018 as a leading Israeli medical device incubator operating under the Israel Innovation Authority. Partners include Boston Scientific, MEDX Venture Group, Sheba Medical Center, and Consensus Business Group. CEO Shai Policker serves as Chairman of Exero Medical's Board.
• Clalit Health ServicescoreStrategic or Co-development Partner · 1 January 2018Israel's largest HMO (health maintenance organization), co-founder of Exero Medical in 2018. Provides clinical expertise and healthcare system perspective for product development.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• SafeHeal: SafeHeal developed a similar intraluminal barrier device to prevent anastomotic leakage following colorectal surgery — most directly comparable to Exero's xBar in target indication, surgical setting, and clinical use case. Acquired by Coloplast in 2021, validating strategic interest in the GI leak-prevention/monitoring category.

Broad incumbents

• Medtronic: Global medical device incumbent with broad GI surgery, surgical instrumentation, and patient monitoring portfolios. Comparable as a potential acquirer/competitor in post-operative tissue monitoring and as a benchmark for surgical sensor commercialization at scale.
• Boston Scientific: Already an indirect investor via MEDX Xelerator and one of the largest medtech acquirers. Comparable as a strategic acquirer for Exero given overlapping GI/surgical endoscope and tissue-monitoring adjacency, and as a benchmark for pathway-to-scale.
• Baxter International: Major manufacturer of surgical drains and post-operative fluid management products. Comparable as Exero's most direct competitor in the standard-of-care surgical drain market that xBar integrates with, and as a potential acquirer of smart-drain innovation.
• Ethicon (Johnson & Johnson MedTech): Surgical solutions division of J&J MedTech with dominant presence in colorectal surgery stapling, sutures, and post-operative care. Comparable in surgical channel reach and GI surgical customer relationships that Exero will need to access.
• Stryker: Diversified medtech with surgical instruments, endoscopy, and surgical informatics products (including OR integration). Comparable as a potential competitor or acquirer given overlap in surgical informatics and OR workflow integration.
• Conmed: Specialty surgical device company with strong presence in general and colorectal surgery, including energy devices, suction/instruments, and post-operative products. Comparable in surgical channel access to Exero's target customer base.
• Cardinal Health: Large medical products distributor and manufacturer with surgical product portfolio. Comparable as a hospital-channel incumbent that Exero will rely on or compete against for adoption of consumable surgical products.
• Applied Medical: Privately-held surgical device company focused on general, colorectal, and bariatric surgery products with direct hospital sales model. Comparable in go-to-market motion (direct hospital sales for surgical consumables) and target surgical specialties.
• B. Braun: Major manufacturer of surgical drains, wound care, and OR integration solutions with global hospital presence. Comparable as a manufacturer of the standard surgical drain that xBar integrates with and a likely competitive threat in smart surgical drainage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/exero-medical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exero Medical